Evidence map›Paper›PMID 33981607›Full record

SynthesisFrontiers in oncology2021

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.

Jiale Sun, Yuxin Lin, Xuedong Wei, Jun Ouyang, Yuhua Huang, Zhixin Ling

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 6 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 6 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Effect ofFrontiers in medicine · 2024
    Pooled it
  2. Pooled it
  3. Head-to-head comparison ofProstate cancer and prostatic diseases · 2023
    Pooled it
  4. Frontiers in oncology · 2023
    Pooled it
  5. Pooled it
  6. Head-to-Head Comparison ofFrontiers in oncology · 2021
    Pooled it
  7. Review
  8. Review
  9. Targeted Molecular Imaging as a Biomarker in Urologic Oncology.The Urologic clinics of North America · 2023
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiale SunDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuxin LinDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xuedong WeiDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jun OuyangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuhua HuangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhixin LingDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
First Affiliated Hospital of Soochow University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

18F-DCFPyLbiochemically recurrent prostate cancerimagingPET/CTprostate-specific membrane antigen

Identifiers

PMID33981607
PMCPMC8107478
OpenAlexW3157824834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.